SeeThruEquity Issues Quarterly Update on Boston Therapeutics and Raises Price Target to $1.12

New York, NY / May 21, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update on Boston Therapeutics (OTCQB: BTHE) for Q1 2014.

“Boston Therapeutics had a solid quarter with revenues up significantly quarter over quarter,” stated Ajay Tandon, CEO of SeeThruEquity. “We are encouraged by the Company’s signing of a marketing agreement with Benchworks, a well known marketing agency that has consistently delivered results for its clients. As a result, we increase our price target to $1.12 per share.”

Recent highlights mentioned in the report include the following:

Strategic marketing agreement for SUGARDOWN(r)
On May 20, 2014, BTHE announced the signing of a strategic marketing agreement with Benchworks SD, LLC (Benchworks), a leading branding and marketing agency, with the goals of driving brand awareness and growing sales of SUGARDOWN(r). In addition, clinical studies indicate that SUGARDOWN(r) can maintain healthy glucose levels even after-meals when sugar tends to spike. Sales of SUGARDOWN grew 88% in 1Q14 to $43,827 compared to $23,336 in 1Q13.

Update on BTI-320
BTHE has maintained a steady stream of announcements related to the development of its leading drug candidate, BTI-320, since reporting positive Phase II clinical trial results for the drug in mid-2013. BTHE recently presented a late-breaking poster relating to BTI-320 at AACE in Las Vegas, Nevada. Kevin H. Mayo, Ph.D. presented the poster, titled "Insight into the Molecular Mechanism of Action of BTI-320, a Non-systemic Novel Drug to Control Serum Glucose Levels in Individuals with Diabetes." BTHE also signed an agreement with pharmaceutical manufacturing company Patheon Inc. to manufacture pharmaceutical-grade tablets of BTI-320 in advance of the company's anticipated IND filing in late 2014 and its planned international Phase III trial for BTI-320 in 2015.

The report is available at: BTHE Update Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, CapitalIQ, FactSet, and Zack’s.

Please review important disclosures on our website at

About SeeThruEquity
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit

About Boston Therapeutics, Inc.
Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI320 (formerly PAZ320), a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes. SUGARDOWN(r) is a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at and


Ajay Tandon
(646) 495-0939


Source: SeeThruEquity

Release ID: 45386